Send to a Colleague

Send to a colleague

Text size

Share Information

After clicking the submit button below, your colleague will receive an email from you containing an Internet link to this site.

The email address you furnish will be used solely to notify the recipient of the link to this site and that you have requested it be sent. The addresses will not be retained or reused.


		AndroGel is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. Androgens are contraindicated in men with carcinoma of the breast or known or suspected carcinoma of the prostate. AndroGel is not indicated for use in women. Geriatric patients treated with androgens may be at an increased risk for the development of prostatic hyperplasia and prostatic carcinoma. The most frequent adverse events reported by ≥5% of patients associated with the consistent use of AndroGel included abnormal lab test, acne, prostate disorder, and application site reaction.

This information is intended for residents of the United States.
For international product information please visit us at http://www.solvay.com.
© 2007 Solvay Pharmaceuticals, Inc.